Raloxifene (Evista) Indications and Dosage
- osteoporosis
- osteoporosis prophylaxis
- uterine leiomyomata †
† non-FDA-approved indication
Raloxifene (Evista) Indications and Dosage
For the treatment of osteoporosis and osteoporosis prophylaxis in postmenopausal women:
Oral dosage:
Postmenopausal adult females: 60 mg PO once daily. Supplement calcium if dietary intake is inadequate.
For the treatment of uterine leiomyomata † in postmenopausal women:
Oral dosage:
Postmenopausal adult females: In one study, raloxifene 60 mg PO once daily in 28-day cycles resulted in reduction in mean uterine and leiomyoma size after 6, 9, and 12 cycles of treatment.
Maximum Dosage Limits:
- Adults: 60 mg/day PO.
- Elderly: 60 mg/day PO.
- Adolescents: Safe and effective use has not been established.
- Children: Safe and effective use has not been established.
Patients with hepatic impairment:
No dosage guidelines are available; however, patients may be at increased risk for side effects. Patients with cirrhosis have up to 2.5-fold higher serum levels of raloxifene than patients with normal hepatic function. Raloxifene has not been studied in patients with severe hepatic impairment.
Patients with renal impairment:
No dosage adjustment is necessary.
[ Last revised: 6/17/2003 2:34:00 PM ]
Related entries
Syndicate
|
